title: High-risk human papillomavirus genotypes distribution in a cohort of HIV-positive women living in Europe: epidemiological implication for vaccination against human papillomavirus.
abstract: BACKGROUND
  Worldwide, human papillomavirus (HPV) 16 and 18 represents 70% of high-risk (HR) HPV found in cervical cancer. However HIV-positive women are more frequently infected by HRHPV other than HPV 16 or 18 (OHR). We aimed to analyse the HRHPV genotype distribution in a cohort of HIV-positive women and to estimate the potential protection offered by the different HPV vaccines.
  
  
  METHODS
  HRHPV genotypes by PCR and cytology were assessed in cervical samples from 508 HIV-positive women prospectively followed in Brussels.
  
  
  RESULTS
  Women characteristics were as follows: African origin (84%), median age 42 years, median CD4 T 555/μl, 89% under combined antiretroviral therapy and 73% with HIVRNA less than 20 copies/ml. HRHPV prevalence was 23% (116/508): 38% had abnormal cytology, 76% carried OHR without HPV 16 or 18 and 11% had concomitant infection by OHR and HPV 16 or 18. The most frequent HRHPV were HPV52 (19.8%), HPV18 (14.6%), HPV31/35/51/58 (12.1% each), HPV56 (9.9%) and HPV16 (9.5%). Less than 30% of women had their HRHPV genotypes included in the bivalent or quadrivalent vaccines against HRHPV 16 and 18; however, 79% had their HRHPV covered by the ninevalent vaccine against HRHPV 16/18/31/33/45/52/58.
  
  
  CONCLUSIONS
  The HRHPV genotypes distribution found in these women living in Europe with a successfully treated HIV is similar to the one found in Central Africa with HRHPV other than HPV16 or 18 retrieved in 87%. In this population, the bivalent or quadrivalent vaccines could offer protection in only 30% of women; however this protection could be extended up to 80% with the ninevalent vaccine.
authors.affiliation: aDepartment of Infectious Diseases and AIDS Reference CentrebDepartment of Gynaecology, Saint-Pierre University HospitalcMolecular Biology LaboratorydDepartment of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
authors.forename: Deborah
authors.initials: D
authors.lastname: Konopnicki
authors.forename: Yannick
authors.initials: Y
authors.lastname: Manigart
authors.forename: Christine
authors.initials: C
authors.lastname: Gilles
authors.forename: Patricia
authors.initials: P
authors.lastname: Barlow
authors.forename: Jérome
authors.initials: J
authors.lastname: De Marchin
authors.forename: Francesco
authors.initials: F
authors.lastname: Feoli
authors.forename: Marc
authors.initials: M
authors.lastname: Delforge
authors.forename: Nathan
authors.initials: N
authors.lastname: Clumeck
authors.forename: Stéphane
authors.initials: S
authors.lastname: De Wit
mesh_terms: D000328:Adult; D000368:Aged; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D001530:Belgium / Q000453:epidemiology; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008875:Middle Aged; D027383:Papillomaviridae / Q000145:classification* / Q000235:genetics / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000453:epidemiology* / Q000821:virology*; D053918:Papillomavirus Vaccines / Q000276:immunology*; D011446:Prospective Studies
chemical_list: D044966:Anti-Retroviral Agents; D053918:Papillomavirus Vaccines